Embargoed until:
Publicly released:
2024-07-09 01:00
In the battle of weight loss drugs, international researchers say that tirzepatide – commonly sold under the names Mounjaro or Zepbound – does a better job of cutting the kilos than semaglutide – commonly sold under the names Ozempic and Wegovy – among overweight and obese people. The researchers investigated the effects of close to 20,000 people taking either drug, and say that while most of them would go on to lose 5% or more of their weight, the effects were greater for tirzepatide.
Journal/conference: JAMA Internal Medicine
Link to research (DOI): 10.1001/jamainternmed.2024.2525
Organisation/s:
Funder: No funding information listed.
Media release
From: JAMA
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or ObesityAbout The Study:Â In this population of adults with overweight or obesity, use of tirzepatide was associated with significantly greater weight loss than semaglutide. Future study is needed to understand differences in other important outcomes.
Attachments:
Note: Not all attachments are visible to the general public